Veraxa Biotech Holding AG
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $275.7M
- Price
- $1.95
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.17%
- Volume
- 80.2K
About
Veraxa Biotech Holding AG is a clinical-stage biopharmaceutical company, formed via a merger with Voyager Acquisition Corp., focusing on developing next-generation cancer therapies such as antibody-drug conjugates (ADCs) and bispecific T-cell engagers. [64, 65]
Quick stats
Shares outstanding141.4M
Computed float42.5M
Float / shares30.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002079109
Websitehttps://www.veraxa.com
AI Summary
AI-generated1/18
minorbullishoperations update
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
VERAXA filed its first patent applications during the first half of 2026 to cover its BiTAC-TCE and BiTAC-ADC platforms and derived therapeutic programs.
The company’s portfolio now includes more than 50 granted or exclusively licensed patents across 14 countries and 26 families, with protection expected to extend through at least 2047.
CEO Christoph Antz stated that the IP strategy reflects the breadth of innovations being pursued in the company’s platforms and click chemistry technologies.